Skip to main content

Beyonttra; Attruby DKSH Healthcare Australia Pty Ltd

Product name
Beyonttra; Attruby
Accepted date
Jan-2026
Active ingredients
acoramidis hydrochloride
Proposed indication
BEYONTTRA/ATTRUBY ( (acoramidis hydrochloride) is proposed as a treatment for adults who have a heart condition (cardiomyopathy) caused by a disease called transthyretin amyloidosis. This disease is caused by the abnormal build up in tissues of a protein called transthyretin. Both normal and altered versions of this protein can cause the disease. It is proposed for people both the inherited or non‑inherited form of this condition.
Application type
A (new medicine)
Publication date
Jan-2026